Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGX-410 (Mifepristone) in HIV-1 Infected Subjects
NCT00352911Phase 2Completed
- Sponsor
- VGX Pharmaceuticals
- Start
- Jul 2006
- Primary completion
- Jun 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus type 1 infection (HIV-1) comparing VGX-410 with Placebo (2 arms). Primary endpoint: Mean Log Change in Viral Load From Baseline (Day 1) to Day 56. Started Jul 2006; status: completed.
02
Drugs
mifepristone
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00352911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352911.